<info type="ChemicalEntity">tacrolimus</info>-associated <info type="DiseaseOrPhenotypicFeature">brachial neuritis</info> after conversion to <info type="ChemicalEntity">everolimus</info> in a <info type="OrganismTaxon">pediatric</info> <info type="OrganismTaxon">renal transplant</info> recipient--case report and review of the literature.

<info type="ChemicalEntity">TAC</info> has been shown to be a potent <info type="ChemicalEntity">immunosuppressive agent</info> for <info type="DiseaseOrPhenotypicFeature">solid organ transplantation</info> in <info type="OrganismTaxon">pediatrics</info>. <info type="DiseaseOrPhenotypicFeature">Neurotoxicity</info> is a potentially serious toxic effect. It is characterized by <info type="DiseaseOrPhenotypicFeature">encephalopathy</info>, <info type="DiseaseOrPhenotypicFeature">headaches</info>, <info type="DiseaseOrPhenotypicFeature">seizures</info>, or <info type="DiseaseOrPhenotypicFeature">neurological deficits</info>. Here, we describe an <info type="OrganismTaxon">eight-and-a-half-yr-old male</info> <info type="OrganismTaxon">renal transplant</info> recipient with right <info type="DiseaseOrPhenotypicFeature">BN</info>. <info type="ChemicalEntity">MRI</info> demonstrated hyperintense <info type="DiseaseOrPhenotypicFeature">T2 signals</info> in the <info type="OrganismTaxon">cervical cord</info> and right <info type="OrganismTaxon">brachial plexus</info> roots indicative of both <info type="DiseaseOrPhenotypicFeature">myelitis</info> and right <info type="DiseaseOrPhenotypicFeature">brachial plexitis</info>. Symptoms persisted for three months despite <info type="ChemicalEntity">TAC</info> dose reduction, administration of <info type="ChemicalEntity">IVIG</info> and four doses of <info type="ChemicalEntity">methylprednisolone</info> pulse therapy. Improvement and eventually full recovery only occurred after <info type="ChemicalEntity">TAC</info> was completely discontinued and successfully replaced by <info type="ChemicalEntity">everolimus</info>.